CDK4 and breast carcinoma: In this study, we used endocrine sensitive and resistant breast cancer cell line pairs to evaluate whether the WEE1 inhibitor, AZD1775, as a single agent or in combination with antiestrogens or CDK4/6 inhibitors, is a reasonable therapy option for inhibiting growth of resistant cells.